Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 70 entries
Sorted by: Best Match Show Resources per page
Spatial Variation in the Quality of American Community Survey Estimates.

Demography

Folch DC, Arribas-Bel D, Koschinsky J, Spielman SE.
PMID: 27541024
Demography. 2016 Oct;53(5):1535-1554. doi: 10.1007/s13524-016-0499-1.

Social science research, public and private sector decisions, and allocations of federal resources often rely on data from the American Community Survey (ACS). However, this critical data source has high uncertainty in some of its most frequently used estimates....

Cite
Folch DC, Arribas-Bel D, Koschinsky J, et al. Spatial Variation in the Quality of American Community Survey Estimates. Demography. 2016;53(5):1535-1554doi: 10.1007/s13524-016-0499-1.
Folch, D. C., Arribas-Bel, D., Koschinsky, J., & Spielman, S. E. (2016). Spatial Variation in the Quality of American Community Survey Estimates. Demography, 53(5), 1535-1554. https://doi.org/10.1007/s13524-016-0499-1
Folch, David C, et al. "Spatial Variation in the Quality of American Community Survey Estimates." Demography vol. 53,5 (2016): 1535-1554. doi: https://doi.org/10.1007/s13524-016-0499-1
Folch DC, Arribas-Bel D, Koschinsky J, Spielman SE. Spatial Variation in the Quality of American Community Survey Estimates. Demography. 2016 Oct;53(5):1535-1554. doi: 10.1007/s13524-016-0499-1. PMID: 27541024.
Copy Download .nbib Format: NLM
A major satellite DNA of soybean is a 92-base pairs tandem repeat.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik

Kolchinsky A, Gresshoff PM.
PMID: 24174019
Theor Appl Genet. 1995 Apr;90(5):621-6. doi: 10.1007/BF00222125.

We report the cloning, sequencing and analysis of the major repetitive DNA of soybean (Glycine max). The repeat, SB92, was cloned as several monomers and trimers produced by digestion with XhoI. The deduced consensus sequence of the repeat is...

Cite
Kolchinsky A, Gresshoff PM. A major satellite DNA of soybean is a 92-base pairs tandem repeat. Theor Appl Genet. 1995;90(5):621-6doi: 10.1007/BF00222125.
Kolchinsky, A., & Gresshoff, P. M. (1995). A major satellite DNA of soybean is a 92-base pairs tandem repeat. TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik, 90(5), 621-6. https://doi.org/10.1007/BF00222125
Kolchinsky, A, and Gresshoff, P M. "A major satellite DNA of soybean is a 92-base pairs tandem repeat." TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik vol. 90,5 (1995): 621-6. doi: https://doi.org/10.1007/BF00222125
Kolchinsky A, Gresshoff PM. A major satellite DNA of soybean is a 92-base pairs tandem repeat. Theor Appl Genet. 1995 Apr;90(5):621-6. doi: 10.1007/BF00222125. PMID: 24174019.
Copy Download .nbib Format: NLM
[The evaluation of the efficacy of new drugs].

Deutsche medizinische Wochenschrift (1946)

KUSCHINSKY G.
PMID: 13261699
Dtsch Med Wochenschr. 1955 Sep 09;80(36):1287-90. doi: 10.1055/s-0028-1116188.

No abstract available.

Cite
KUSCHINSKY G. Uber die Beurteilung der Wirkung neuer Arzneimittel. [The evaluation of the efficacy of new drugs]. Dtsch Med Wochenschr. 1955;80(36):1287-90doi: 10.1055/s-0028-1116188.
KUSCHINSKY, G. (1955). Uber die Beurteilung der Wirkung neuer Arzneimittel. [The evaluation of the efficacy of new drugs]. Deutsche medizinische Wochenschrift (1946), 80(36), 1287-90. https://doi.org/10.1055/s-0028-1116188
KUSCHINSKY, G. "Uber die Beurteilung der Wirkung neuer Arzneimittel." [The evaluation of the efficacy of new drugs]. Deutsche medizinische Wochenschrift (1946) vol. 80,36 (1955): 1287-90. doi: https://doi.org/10.1055/s-0028-1116188
KUSCHINSKY G. Uber die Beurteilung der Wirkung neuer Arzneimittel. [The evaluation of the efficacy of new drugs]. Dtsch Med Wochenschr. 1955 Sep 09;80(36):1287-90. doi: 10.1055/s-0028-1116188. German. PMID: 13261699.
Copy Download .nbib Format: NLM
5S-RNA genes of barley are located on the second chromosome.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik

Kolchinsky A, Kanazin V, Yakovleva E, Gazumyan A, Kole C, Ananiev E.
PMID: 24220965
Theor Appl Genet. 1990 Sep;80(3):333-6. doi: 10.1007/BF00210068.

The genes coding for 5S RNA in barley were cloned, sequenced, and their cluster was assigned to chromosome 2 using wheat-barley chromosome addition lines. High-resolution gel-electrophoresis of DNA and subsequent hybridization revealed new details of the organization of 5S...

Cite
Kolchinsky A, Kanazin V, Yakovleva E, et al. 5S-RNA genes of barley are located on the second chromosome. Theor Appl Genet. 1990;80(3):333-6doi: 10.1007/BF00210068.
Kolchinsky, A., Kanazin, V., Yakovleva, E., Gazumyan, A., Kole, C., & Ananiev, E. (1990). 5S-RNA genes of barley are located on the second chromosome. TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik, 80(3), 333-6. https://doi.org/10.1007/BF00210068
Kolchinsky, A, et al. "5S-RNA genes of barley are located on the second chromosome." TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik vol. 80,3 (1990): 333-6. doi: https://doi.org/10.1007/BF00210068
Kolchinsky A, Kanazin V, Yakovleva E, Gazumyan A, Kole C, Ananiev E. 5S-RNA genes of barley are located on the second chromosome. Theor Appl Genet. 1990 Sep;80(3):333-6. doi: 10.1007/BF00210068. PMID: 24220965.
Copy Download .nbib Format: NLM
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

SpringerPlus

Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M.
PMID: 24455463
Springerplus. 2014 Jan 03;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 03.

BACKGROUND: Dose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy...

Cite
Hohloch K, Zwick C, Ziepert M, et al. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springerplus. 2014;3:5doi: 10.1186/2193-1801-3-5.
Hohloch, K., Zwick, C., Ziepert, M., Hasenclever, D., Kaiser, U., Engert, A., Höffkes, H. G., Kroschinsky, F., Mesters, R., Feller, A. C., Löffler, M., Trümper, L., Pfreundschuh, M. (2014). Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. SpringerPlus, 35. https://doi.org/10.1186/2193-1801-3-5
Hohloch, Karin, et al. "Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL." SpringerPlus vol. 3 (2014): 5. doi: https://doi.org/10.1186/2193-1801-3-5
Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springerplus. 2014 Jan 03;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 03. PMID: 24455463; PMCID: PMC3890437.
Copy Download .nbib Format: NLM
The case for spatial analysis in evaluation to reduce health inequities.

Evaluation and program planning

Koschinsky J.
PMID: 22469340
Eval Program Plann. 2013 Feb;36(1):172-6. doi: 10.1016/j.evalprogplan.2012.03.004. Epub 2012 Mar 14.

The article begins by giving an overview of spatial thinking concepts that are relevant to evaluation. The article relates the spatial perspective to both a realist evaluation and a randomized control trial perspective in evaluation to demonstrate the benefits...

Cite
Koschinsky J. The case for spatial analysis in evaluation to reduce health inequities. Eval Program Plann. 2012;36(1):172-6doi: 10.1016/j.evalprogplan.2012.03.004.
Koschinsky, J. (2013). The case for spatial analysis in evaluation to reduce health inequities. Evaluation and program planning, 36(1), 172-6. https://doi.org/10.1016/j.evalprogplan.2012.03.004
Koschinsky, Julia. "The case for spatial analysis in evaluation to reduce health inequities." Evaluation and program planning vol. 36,1 (2013): 172-6. doi: https://doi.org/10.1016/j.evalprogplan.2012.03.004
Koschinsky J. The case for spatial analysis in evaluation to reduce health inequities. Eval Program Plann. 2013 Feb;36(1):172-6. doi: 10.1016/j.evalprogplan.2012.03.004. Epub 2012 Mar 14. PMID: 22469340.
Copy Download .nbib Format: NLM
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Investigational new drugs

Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N.
PMID: 32578153
Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9.

No abstract available.

Cite
Kroschinsky F, Middeke JM, Janz M, et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021;39(1):285-286doi: 10.1007/s10637-020-00964-9.
Kroschinsky, F., Middeke, J. M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S. J., Kim, T. M., Ottmann, O., Chromik, J., Quinson, A. M., von Wangenheim, U., Burkard, U., Berk, A., & Schmitz, N. (2021). Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Investigational new drugs, 39(1), 285-286. https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky, Frank, et al. "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma." Investigational new drugs vol. 39,1 (2021): 285-286. doi: https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. PMID: 32578153; PMCID: PMC8025277.
Copy Download .nbib Format: NLM
Entropy production given constraints on the energy functions.

Physical review. E

Kolchinsky A, Wolpert DH.
PMID: 34654169
Phys Rev E. 2021 Sep;104(3):034129. doi: 10.1103/PhysRevE.104.034129.

We consider the problem of driving a finite-state classical system from some initial distribution p to some final distribution p^{'} with vanishing entropy production (EP), under the constraint that the driving protocols can only use some limited set of...

Cite
Kolchinsky A, Wolpert DH. Entropy production given constraints on the energy functions. Phys Rev E. 2021;104(3):034129doi: 10.1103/PhysRevE.104.034129.
Kolchinsky, A., & Wolpert, D. H. (2021). Entropy production given constraints on the energy functions. Physical review. E, 104(3), 034129. https://doi.org/10.1103/PhysRevE.104.034129
Kolchinsky, Artemy, and Wolpert, David H. "Entropy production given constraints on the energy functions." Physical review. E vol. 104,3 (2021): 034129. doi: https://doi.org/10.1103/PhysRevE.104.034129
Kolchinsky A, Wolpert DH. Entropy production given constraints on the energy functions. Phys Rev E. 2021 Sep;104(3):034129. doi: 10.1103/PhysRevE.104.034129. PMID: 34654169.
Copy Download .nbib Format: NLM
Loss-of-Function Mutations of .

Cancers

Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM.
PMID: 33926021
Cancers (Basel). 2021 Apr 26;13(9). doi: 10.3390/cancers13092095.

Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The

Cite
Eckardt JN, Stasik S, Kramer M, et al. Loss-of-Function Mutations of . Cancers (Basel). 2021;13(9)doi: 10.3390/cancers13092095.
Eckardt, J. N., Stasik, S., Kramer, M., Röllig, C., Krämer, A., Scholl, S., Hochhaus, A., Crysandt, M., Brümmendorf, T. H., Naumann, R., Steffen, B., Kunzmann, V., Einsele, H., Schaich, M., Burchert, A., Neubauer, A., Schäfer-Eckart, K., Schliemann, C., Krause, S. W., Herbst, R., Hänel, M., Frickhofen, N., Noppeney, R., Kaiser, U., Baldus, C. D., Kaufmann, M., Rácil, Z., Platzbecker, U., Berdel, W. E., Mayer, J., Serve, H., Müller-Tidow, C., Ehninger, G., Stölzel, F., Kroschinsky, F., Schetelig, J., Bornhäuser, M., Thiede, C., & Middeke, J. M. (2021). Loss-of-Function Mutations of . Cancers, 13(9), . https://doi.org/10.3390/cancers13092095
Eckardt, Jan-Niklas, et al. "Loss-of-Function Mutations of ." Cancers vol. 13,9 (2021). doi: https://doi.org/10.3390/cancers13092095
Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Loss-of-Function Mutations of . Cancers (Basel). 2021 Apr 26;13(9). doi: 10.3390/cancers13092095. PMID: 33926021; PMCID: PMC8123716.
Copy Download .nbib Format: NLM
Copper-binding ligands in deep-sea pore waters of the Pacific Ocean and potential impacts of polymetallic nodule mining on the copper cycle.

Scientific reports

Paul SAL, Zitoun R, Noowong A, Manirajah M, Koschinsky A.
PMID: 34531446
Sci Rep. 2021 Sep 16;11(1):18425. doi: 10.1038/s41598-021-97813-3.

The release of potentially toxic metals, such as copper (Cu), into the water column is of concern during polymetallic nodule mining. The bioavailability and thus toxicity of Cu is strongly influenced by its speciation which is dominated by organic...

Cite
Paul SAL, Zitoun R, Noowong A, et al. Copper-binding ligands in deep-sea pore waters of the Pacific Ocean and potential impacts of polymetallic nodule mining on the copper cycle. Sci Rep. 2021;11(1):18425doi: 10.1038/s41598-021-97813-3.
Paul, S. A. L., Zitoun, R., Noowong, A., Manirajah, M., & Koschinsky, A. (2021). Copper-binding ligands in deep-sea pore waters of the Pacific Ocean and potential impacts of polymetallic nodule mining on the copper cycle. Scientific reports, 11(1), 18425. https://doi.org/10.1038/s41598-021-97813-3
Paul, Sophie A L, et al. "Copper-binding ligands in deep-sea pore waters of the Pacific Ocean and potential impacts of polymetallic nodule mining on the copper cycle." Scientific reports vol. 11,1 (2021): 18425. doi: https://doi.org/10.1038/s41598-021-97813-3
Paul SAL, Zitoun R, Noowong A, Manirajah M, Koschinsky A. Copper-binding ligands in deep-sea pore waters of the Pacific Ocean and potential impacts of polymetallic nodule mining on the copper cycle. Sci Rep. 2021 Sep 16;11(1):18425. doi: 10.1038/s41598-021-97813-3. PMID: 34531446; PMCID: PMC8446087.
Copy Download .nbib Format: NLM
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.

Cancer chemotherapy and pharmacology

Heuschkel S, Kretschmann T, Teipel R, von Bonin S, Richter S, Quick S, Alakel N, Röllig C, Balaian E, Kroschinsky F, Knoth H, Bornhäuser M, von Bonin M.
PMID: 34669022
Cancer Chemother Pharmacol. 2022 Jan;89(1):41-48. doi: 10.1007/s00280-021-04361-8. Epub 2021 Oct 20.

PURPOSE: High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The recommended dose of glucarpidase is 50...

Cite
Heuschkel S, Kretschmann T, Teipel R, et al. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemother Pharmacol. 2021;89(1):41-48doi: 10.1007/s00280-021-04361-8.
Heuschkel, S., Kretschmann, T., Teipel, R., von Bonin, S., Richter, S., Quick, S., Alakel, N., Röllig, C., Balaian, E., Kroschinsky, F., Knoth, H., Bornhäuser, M., & von Bonin, M. (2022). Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer chemotherapy and pharmacology, 89(1), 41-48. https://doi.org/10.1007/s00280-021-04361-8
Heuschkel, Sandra, et al. "Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury." Cancer chemotherapy and pharmacology vol. 89,1 (2022): 41-48. doi: https://doi.org/10.1007/s00280-021-04361-8
Heuschkel S, Kretschmann T, Teipel R, von Bonin S, Richter S, Quick S, Alakel N, Röllig C, Balaian E, Kroschinsky F, Knoth H, Bornhäuser M, von Bonin M. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemother Pharmacol. 2022 Jan;89(1):41-48. doi: 10.1007/s00280-021-04361-8. Epub 2021 Oct 20. PMID: 34669022.
Copy Download .nbib Format: NLM
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.

Cytometry. Part B, Clinical cytometry

Oelschlaegel U, Oelschlaeger L, von Bonin M, Kramer M, Sockel K, Mohr B, Wagenfuehr L, Kroschinsky F, Bornhaeuser M, Platzbecker U.
PMID: 34390327
Cytometry B Clin Cytom. 2021 Aug 14; doi: 10.1002/cyto.b.22030. Epub 2021 Aug 14.

BACKGROUND: Flow cytometry (FCM) is a co-criterion in myelodysplastic syndromes (MDS) diagnostics according to the WHO classification. The presented study compared diagnostic power and prognostic impact of different FCM-based scores.METHODS: A total of 807 bone marrow (BM) samples of...

Cite
Oelschlaegel U, Oelschlaeger L, von Bonin M, et al. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact. Cytometry B Clin Cytom. 2021;doi: 10.1002/cyto.b.22030.
Oelschlaegel, U., Oelschlaeger, L., von Bonin, M., Kramer, M., Sockel, K., Mohr, B., Wagenfuehr, L., Kroschinsky, F., Bornhaeuser, M., & Platzbecker, U. (2021). Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact. Cytometry. Part B, Clinical cytometry, . https://doi.org/10.1002/cyto.b.22030
Oelschlaegel, Uta, et al. "Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact." Cytometry. Part B, Clinical cytometry vol. (2021). doi: https://doi.org/10.1002/cyto.b.22030
Oelschlaegel U, Oelschlaeger L, von Bonin M, Kramer M, Sockel K, Mohr B, Wagenfuehr L, Kroschinsky F, Bornhaeuser M, Platzbecker U. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact. Cytometry B Clin Cytom. 2021 Aug 14; doi: 10.1002/cyto.b.22030. Epub 2021 Aug 14. PMID: 34390327.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 70 entries